Piramal Pharma
₹197.73+3.30 (+1.70%)as of 2026-10-16
- Market Cap
- ₹26,346Cr.
- P/E Ratio
- —
- P/B Ratio
- 3.22
- EPS (TTM)
- —
- Day Range
- ₹193.6 – ₹198.75
- Div Yield
- 0%
- ROCE
- 2.52%
- ROE
- -3.83%
52W Low: ₹13252W High: ₹232
Themes:💊 Pharma & CDMO
Descriptive screens built from published data — not investment advice.
At a glance
- Sales have grown 8.0% a year over three years.
- Debt is 0.70× its shareholders’ equity.
From reported financials and exchange prices. Descriptive only, not advice.
Piramal_Pharma — Price
Interval
Style
Failed: 503
Evenstocks Score
Middle third
Overall
Valuation
Quality
Fundamental
Growth
Investment Checklist
Quick assessment based on key parametersPerformance
N/ATrailing return unavailableValuation
N/AP/E: N/A | P/B: 3.22Growth
ModestSales CAGR — 3Y: 8% · 1Y: 1%Profitability
Low MarginROCE: 2.52% | ROE: -3.83%Key Metrics
Valuation
Price / Sales 2.86x
Price / FCF 34.0x
Book Value ₹61.4
Margins & returns
Operating Margin 11%
Net Margin -3.4%
Return on Assets -1.8%